Herbert Tirjer, DO in Milwaukie, OR - Urology

Herbert Tirjer, DO is a Urology physician based in Milwaukie, Oregon. Herbert Tirjer is licensed to practice in Oregon (license number DO14687) and his current practice location is 10330 Se 32nd Ave, Suite 226, Milwaukie, Oregon. He can be reached at his office (for appointments etc.) via phone at (503) 659-1120.

NPI number for Herbert Tirjer is 1336101336 and his current mailing address is 10330 Se 32nd Ave, Suite 226, Milwaukie, Oregon. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1336101336.

Contact Information

	Herbert Tirjer, DO
	10330 Se 32nd Ave, Suite 226, Milwaukie, OR 97222-6587
	(503) 659-1120
	Not Available

Physician's Profile

Full Name	Herbert Tirjer
Gender	Male
Speciality	Urology
Location	10330 Se 32nd Ave, Milwaukie, Oregon
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1336101336
Provider Enumeration Date: 04/05/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Herbert Tirjer such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1336101336	NPI	-	NPPES
173708	Medicaid	OR

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	DO14687 (Oregon)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Herbert Tirjer is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Herbert Tirjer, DO 10330 Se 32nd Ave, Suite 226, Milwaukie, OR 97222-6587 Ph: () -	Herbert Tirjer, DO 10330 Se 32nd Ave, Suite 226, Milwaukie, OR 97222-6587 Ph: (503) 659-1120

News Archive

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

Home test kits provide young women with a safe and effective means for protecting their sexual reproductive health

Researchers at Johns Hopkins say they have evidence that more than one-third of young women are willing and able to use a free, easily available home test kit to privately and accurately learn if they are infected with Chlamydia trachomatis, the most common sexually transmitted disease (STD) in this group.

Supercomputer dramatically accelerates genome analysis

Although the time and cost of sequencing an entire human genome has plummeted, analyzing the resulting three billion base pairs of genetic information from a single genome can take many months.

CSU study offers new strategies to address complex challenges of global food production

Agriculture now produces more than enough calories to meet basic human dietary needs worldwide. Despite this seeming abundance, one out of eight people do not have access to sufficient food.

Scientists use mathematical tools to identify animal species that transmit diseases to humans

Spanish and US scientists have successfully identified animal species that can transmit more diseases to humans by using mathematical tools similar to those applied to the study of social networks like Facebook or Twitter.

Herbert Tirjer, DO - Urology in Milwaukie, OR